Iovance Biotherapeutics
Develops and commercializes cancer immunotherapies using tumor-infiltrating lymphocytes.
Company facts
- Founded
- 2007
- Employees
- 975
- Headquarters
- United States
- Type
- Public
- Listed
- NASDAQ: IOVA
About
Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing tumor‑infiltrating lymphocyte (TIL) therapies and other autologous cell‑based immuno‑oncology treatments. Leveraging its proprietary TIL platform, Iovance delivers personalized cell therapies that harness patients’ immune systems to target a range of solid tumors, with promising clinical data supporting its approach. The company also pursues next‑generation cell therapies, including gene‑edited products, to expand therapeutic options for cancer patients. Headquartered in the San Francisco Bay Area, Iovance operates a state‑of‑the‑art manufacturing facility (the Iovance Cell Therapy Center) in Philadelphia and a research site in Tampa, Florida. As it scales its commercial launch and advances R&D, Iovance seeks talent to support manufacturing, clinical development, and commercial operations, offering opportunities to contribute to innovative cancer treatments.